Skip to main content
Premium Trial:

Request an Annual Quote

Eilean Therapeutics to Evaluate FLT3 Inhibitor Lomonitinib in Beat AML Trial

NEW YORK – Eilean Therapeutics this week said it will evaluate the investigational FLT3/IRAK4 inhibitor lomonitinib in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia (AML) in an arm of the Leukemia & Lymphoma Society's Beat AML master clinical trial.

The lomonitinib arm will be a Phase I sub-study within the Beat AML trial. It will also be the first cohort in which researchers will evaluate a precision medicine treatment in patients whose disease has relapsed or not responded to prior treatment, according to Eilean.

Lomonitinib is designed to inhibit clinically relevant FLT3 mutations, including FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD), as well as mutations in genes associated with resistance to FLT3 inhibitors such as IRAK4.

"Working with partners like Eilean to evaluate their new and potentially breakthrough approaches to AML treatment in the Beat AML framework will speed the process of bringing new treatments to both newly diagnosed patients and those previously treated with other therapies," Ashley Yocum, Leukemia & Lymphoma Society's executive research lead for Beat AML, said in a statement.

In the Beat AML trial, launched in 2016, investigators are matching patients to treatments in clinical trial arms based on the molecular characteristics driving their leukemia. In the trial, researchers compare the activity of investigational precision oncology drugs against active comparator arms that include standard-of-care treatments.